Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...

Viking Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -16.62%. The profit margin, also known as the revenue ratio or gross ...

Highlights,Viking Therapeutics CEO Brian Lian to present on January 13, 2025, at the J.P. Morgan Healthcare Conference,The ...

The transaction, which took... In a recent transaction, Brian Lian, the President and CEO of Viking Therapeutics, Inc. (NASDAQ:VKTX), sold 1,000 shares of the company's common stock. The sale ...

"I like Ryan Grigson," NFL super agent Drew Rosenhaus said this week on The Pat McAfee Show. "I've seen him work with the Vikings. Coach Flores is a stud. If someone can get Grigson and Flores as a ...

Vikings head coach Kevin O’Connell has done a terrific job this season. But his future in Minnesota seems far more certain ...

Flores, who previously served as Dolphins head coach from 2019-21, has had interview requests from the Jets and Bears as he ...